The case for & against
Bull & Bear analysis
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a key player in the medical device industry, specializing in innovative vascular access solutions, particularly focus on products for the treatment of peripheral vascular diseases such as grafts, angioplasty balloons, and stents. The company operates globally with a strategic emphasis on expanding its international footprint, driven by strong product demand and recent regulatory approvals for its Autograph product line. Positioned in a growing market for vascular interventions, LeMaitre exhibits robust growth potential, especially as it leverages its direct-to-hospital sales model and strategic pricing strategies.
Bull says
- ↑11% YoY revenue growth to $71.5M, gross margin up to 72.7%, EPS +42%.
- ↑International Autograph sales set to reach $10M in 2026, up from $4M.
- ↑$367M cash balance supports $100M share repurchase and 25% dividend increase.
- ↑Gross margin improved 350 bps YoY via pricing and manufacturing efficiencies.
- ↑Sales force to expand from 164 to ~175 reps by end-2026 to drive growth.
- ↑Strong balance sheet quality, ample liquidity, positive profitability and earnings yield.
Bear says
- ↓Regulatory approval delays in Europe could stall Autograph launch timing.
- ↓Operating expenses rose 6% YoY to $30.6M, limiting earnings visibility.
- ↓Margin heavily reliant on price increases, vulnerable to competitive pricing pressure.
- ↓$65M in inventory build-up raises supply-chain and cash-flow risks.
- ↓Analyst downgrade to Hold highlights cautious market sentiment.
- ↓Weak momentum factors and negative book-to-price and dividend yield signals.
Investment themes with LMAT
Devices and instruments for medical treatment
Earnings Call · Q1 2025 · Mgmt. Guidance
Transcript signals
Bull points
- Q1 sales were stronger than our February 27th guidance. 13% organic and 12% reported growth was led by graphs up 17% and carotid chunks up 14%. We posted sales records in all five of our categories, graphs, carotid chunks, catheters, valvetomes, and patches.
- We expect to sign a transition agreement with our Czech distributor shortly and should log our first direct sale in August. Also in Europe, we've just received our MDR CE mark for Artograph, and the European launch will begin presently. Artograph, a biologic graft used primarily in AV access and peripheral bypass, was the company's largest U.S. product in 2024 with $37 million in U.S. sales.
- In summary, Q1 sales momentum, our continued office and Salesforce build-out, and our regulatory progress allow us to increase our 2025 reported sales guidance to $245 million from 239 previously. And our organic sales guidance has advanced to 13% from 10% previously.
Bear points
- Operating expenses in Q1 2025 were $28.8 million, an increase of 16% versus Q1 2024. The increase was driven largely by higher compensation expenses, including the addition of 21 more sales professionals and higher non-compensation sales-related expenses.
- Operating expenses in Q1 2025 were $28.8 million, an increase of 16% versus Q1 2024. The increase was driven largely by higher compensation expenses, including the addition of 21 more sales professionals and higher non-compensation sales-related expenses.
- we anticipate low substitution risk, and we believe we can raise prices to offset most potential tariffs. China accounted for less than 1% of our total annual revenue.